relugolix - Profile

What are the generic drug sources for relugolix and what is the scope of patent protection?

Relugolix is the generic ingredient in one branded drug marketed by Sumitomo Pharma Am and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Relugolix has one hundred and ninety patent family members in thirty-seven countries.

Summary for relugolix

International Patents:	190
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for relugolix

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for relugolix

Constraining patent/regulatory exclusivity:

7,300,935

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for RELUGOLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORGOVYX	Tablets	relugolix	120 mg	214621	6	2024-12-18

US Patents and Regulatory Information for relugolix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes	12,144,809
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes	11,583,526
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes	12,336,990
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes	12,097,198
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes	10,449,191

Expired US Patents for relugolix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020	8,058,280
Sumitomo Pharma Am	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020	8,735,401

EU/EMA Drug Approvals for relugolix

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Orgovyx	relugolix	EMEA/H/C/005353Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.	Authorised	no	no	no	2022-04-29

International Patents for relugolix

Country	Patent Number	Title	Estimated Expiration
Australia	2016224503
Brazil	112017018173
Canada	2978223
China	107249590
Cyprus	1126118

Supplementary Protection Certificates for relugolix

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1591446	SPC/GB21/065	United Kingdom		PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REGISTERED: UK EU/1/21/1565(NI) 20210720; UK FURTHER MA ON IPSUM 20210720
1591446	CR 2021 00048	Denmark		PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REG. NO/DATE: EU/1/21/1565 20210720
1591446	301158	Netherlands		PRODUCT NAME: RELUGOLIX OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1565 20210720
1591446	C 2021 047	Romania		PRODUCT NAME: RELUGOLIX SAU O SARE A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/21/1565; DATE OF NATIONAL AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1565; DATE OF FIRST AUTHORISATION IN EEA: 20210716
1591446	122022000002	Germany		PRODUCT NAME: RELUGOLIX ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1565 20210716

Relugolix: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist developed by Myovant Sciences (acquired by Sumitomo Pharma in 2022), presents significant investment opportunities rooted in its broad therapeutic applications, competitive positioning, and evolving market landscape. This analysis explores the drug's current market status, competitive landscape, regulatory trajectory, and forecasted financial performance to aid strategic decision-making.

---

What is Relugolix?

Relugolix is marketed as relugolix (brand name: Orgovyx for prostate cancer and Hembilra in some regions) and is approved for:

• Prostate cancer – once-daily oral therapy (approved in US, EU, Japan).
• Uterine fibroids – approved under the name MyFembree or Relumina (Japan).
• Endometriosis – as part of combination therapy.

It is positioned as an oral alternative to injectable GnRH therapies, offering benefits such as improved compliance and convenience.

---

Market Overview and Dynamics

Parameter	Details
Therapeutic Area	Oncology, Gynecology
Primary Indications	Prostate cancer, Uterine fibroids, Endometriosis
Market Size (2022)	$XX billion (prostate, uterine fibroids, endometriosis collectively)
Global Market Growth	CAGR of approximately X% (2022-2027)
Key Competitors	Leuprorelin (Lupron), Goserelin, Degarelix, Relcovaptan (early-stage)
Regulatory Approvals	US (FDA, 2019), EU, Japan, others

Market Entry Challenges:

• Competition within established injectable therapies.
• Prescriber and patient adoption of oral alternatives.
• Reimbursement landscape.

Market Drivers:

• Demand for oral GnRH antagonists.
• Preference for outpatient treatments.
• Rising prevalence of prostate cancer and fibroids.

Market Restraints:

• Generic competition.
• Side effect profiles.
• Need for long-term safety data.

---

Clinical and Regulatory Milestones

Milestone Date	Event	Implication
2019 (May)	FDA approval for prostate cancer	Validates commercial viability
2020	Launch in US	Revenue begins recognition
2021	Japan approval for uterine fibroids	Expanded market scope
2022	Acquisition of Myovant by Sumitomo Pharma	Accelerates commercialization

Financial Trajectory and Investment Outlook

Parameter	Current Status / 2023 Forecast	Comments
Revenue (2022)	$XXX million	Driven by initial sales in US, Japan
Projected Revenue (2027)	$XX billion	Compound annual growth rate (CAGR) of X% based on market penetration, pipeline growth
R&D Investment	$XX million (2022)	Focused on expanding indications and formulations
Profitability	Expected to turn EBITDA positive by 2024	Given increasing sales and scaled manufacturing

Key Revenue Drivers:

• Prostate cancer segment: Largest segment, stable OEM demand.
• Uterine fibroids & Endometriosis: Rapidly growing with expanding indications.

Market Penetration Strategy:

• Combining direct-to-consumer campaigns.
• Physician education initiatives.
• Strategic partnerships in emerging markets.

Key Risks to Financial Trajectory:

• Market entry barriers.
• Competition from injectable GnRH analogs.
• Regulatory delays or additional approval requirements.

---

Comparison with Competitors and Alternatives

Drug	Type	Approval Year	Route	Annual Cost (USD)	Market Share (Estimated)	Advantages	Disadvantages
Relugolix	GnRH antagonist	2019 (FDA)	Oral	XXX	X%	Oral, once-daily, efficacy	Competition, side effects
Leuprorelin (Lupron)	GnRH agonist	1985	Injection	XXX	XX%	Proven long-term safety	Injectable, side effects
Goserelin	GnRH analog	1987	Injection	XXX	X%	Cost-effective	Invasive delivery
Degarelix	GnRH antagonist	2018	Injection	XXX	X%	Rapid testosterone reduction	Injection site reactions

Market Expansion Opportunities

• Additional indications: Breast cancer, endometriosis refractory to current therapies.
• Formulation improvements: Long-acting formulations or combination therapies.
• Geographical expansion: China, India, Latin America.

---

Regulatory and Policy Environment

Region	Status	Considerations
US	Approved (2019)	CMS reimbursement policies favor oral therapies
EU	Approved	EMA guidelines focus on long-term safety data
Japan	Approved for uterine fibroids	National health insurance integration

Policy Factors Impacting Financials:

• Reimbursement policies can influence price points.
• Patent protection until approximately 2030 (patent applications filed in multiple regions).
• Potential biosimilar competition (though less relevant for small molecules).

---

Investment Risks and Considerations

Risk Factor	Potential Impact	Mitigation Strategies
Competitive pressure	Market share erosion	Diversify indications, expand pipeline
Regulatory delays	Revenue postponements	Continuous compliance and proactive engagement
Patent challenges	Generic entry risks	Vigilant patent defense, pipeline innovation
Market acceptance	Slower adoption	Physician education, patient awareness campaigns

---

Key Takeaways

• Relugolix is positioned as a promising oral GnRH antagonist with a diversified application across prostate cancer, fibroids, and endometriosis.
• Market growth is driven by preferences for oral therapies and expanding indications, with projected revenues reaching billions by 2027.
• Competitive landscape features longstanding injectable therapies; however, relugolix’s convenience gives it a competitive edge.
• Regulatory support and expanding geographical approvals bolster its market potential.
• Risks include aggressive competition, regulatory hurdles, and pricing pressures, which companies are actively strategizing to mitigate.

---

FAQs

1. What is the current market penetration of relugolix in its key indications?
Relugolix's penetration remains moderate, with rapid growth in the US and Japan since approval. Market share is increasing, though it still faces competition from injectable GnRH therapies.

2. How does relugolix’s pricing compare with injectable alternatives?
Initially, relugolix's cost is comparable or slightly higher than oral medications but offers significant convenience advantages. Long-term cost-effectiveness depends on adherence and avoids administration fees associated with injections.

3. What are the major barriers to wider adoption of relugolix?
Physician familiarity with established injectables, patient preference for injections, reimbursement policies, and regional regulatory hesitations.

4. What are the key pipeline developments for relugolix?
Ongoing development includes follow-on formulations (e.g., long-acting), additional indications like breast cancer, and potential combination therapies.

5. How might patent expirations influence relugolix’s market exclusivity?
Patents extend until roughly 2030, providing a period of market exclusivity. Generic competition is unlikely until patents lapse, but biosimilar competition is less relevant for small molecules.

---

References

[1] Myovant Sciences Press Releases, 2022.
[2] FDA Approval Documents, 2019.
[3] Market Research Reports, 2022-2023.
[4] EMA and Japanese approvals, 2021-2022.
[5] Industry analyst forecasts, 2022-2027.

---

Note: Market figures and projections are based on the latest available sources and may vary with further data updates.